Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

DMID 23-0015 ; Fièvre de Lassa CVD 1000

21 septembre 2026 mis à jour par: Wilbur Chen, MD, MS

Une étude de phase 1, randomisée, à l'aveugle du receveur et de l'observateur, avec augmentation de dose, pour évaluer l'innocuité, la réactogénicité et l'immunogénicité de deux doses de vaccin monovalent contre la fièvre de Lassa à vecteur rage (LASSARAB) administrées avec du 3D-(6-Acyl) PHAD -SE (aPHAD-SE) Adjuvant chez les adultes en bonne santé

This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen. The antigen will be presented on a genetically modified and attenuated rabies vector expressing both the rabies glycoprotein (GP) antigen and the Lassa GPC. The inactivated chimeric virus is delivered with a toll-like receptor (TLR-4)-activating oil-in-water emulsion adjuvant. Studies using this vaccine administered as a prime-boost series in mice and non-human primates, and then challenged with Lassa virus demonstrated significant protection against Lassa fever. Given that the vaccine backbone is an attenuated and inactivated rabies virus expressing rabies GP, this vaccine will also be evaluated for immunogenicity against rabies virus.

Aperçu de l'étude

Description détaillée

Lassa fever is a zoonotic infection endemic in West Africa and is spread by the Lassa virus, an arenavirus causing hemorrhagic fever. Up to 300,000 Lassa fever infections occur annually and while disease is often mild, in a subset of individuals disease is characterized by severe anemia, bleeding, encephalopathy, respiratory failure, shock, and high mortality. In some regions of West Africa, up to 15% of hospital admissions are secondary to Lassa fever, and an estimated 5,000 deaths occur annually. During epidemics of disease, case-fatality rates may reach as high as 50% in hospitalized patients. Approximately one-third of infected individuals will develop hearing loss regardless of disease severity, and in a proportion of patients, permanent deafness occurs.

Prevention of illness through vaccination is a critical goal in reducing the burden of disease from Lassa fever. There are currently no vaccines or therapeutics demonstrated to be efficacious in the prevention or treatment of Lassa fever. This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen. The antigen will be presented on a genetically modified and attenuated rabies vector expressing both the rabies glycoprotein (GP) antigen and the Lassa GPC. The inactivated chimeric virus is delivered with a toll-like receptor (TLR-4)-activating oil-in-water emulsion adjuvant. Studies using this vaccine administered as a prime-boost series in mice and non-human primates, and then challenged with Lassa virus demonstrated significant protection against Lassa fever. Given that the vaccine backbone is an attenuated and inactivated rabies virus expressing rabies GP, this vaccine will also be evaluated for immunogenicity against rabies virus.

Type d'étude

Interventionnel

Inscription (Réel)

54

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Maryland
      • Baltimore, Maryland, États-Unis, 21201
        • University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 50 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Provides written informed consent prior to the initiation of any trial procedures.

  2. Able to understand and agrees to comply with all planned trial procedures and be available for all study visits.

  3. Age ≥ 18 and ≤50 years at time of enrollment.

  4. In good general health and without clinically significant medical, psychiatric, chronic or intermittent health conditions including those listed in Exclusion Criteria

  5. Participants of childbearing potential must have a negative serum human chronic gonadotropin (HCG) pregnancy test at screening and a negative urine HCG pregnancy test within 24 hours prior to the study vaccination.

  6. Participants of childbearing potential in a heterosexual relationship agree to use of highly effective contraception beginning at the time of the screening visit through Day 61 (32 days after the last study treatment).

  7. Vital signs and Body Mass Index (BMI) are in the following ranges at screening:

    • Oral temperature is less than 100.4°F (38.0°C).
    • Pulse is 47 to 100 beats per minute, inclusive.
    • Systolic blood pressure (SBP) is 85 to 140 mmHg, inclusive.
    • Diastolic blood pressure(DBP) is 55 to 90 mmHg, inclusive.
    • BMI of 18 kilograms/square meter (kg/m2) (inclusive) to <35 kg/m2
  8. Has a negative test result for hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV) types 1 or 2 antibodies at screening.

  9. Has a negative rabies neutralizing antibody test at screening (< 0.5 IU/mL in RFFIT assay)

  10. Screening hematology tests (white blood cells, hemoglobin, and platelets) and screening chemistry tests (alanine transaminase, creatine, and total bilirubin) are within acceptable parameters

  11. Must agree to the collection and storage of residual biological specimens and additional clinical specimens for secondary research use

  12. Agreement to adhere to Lifestyle Considerations during the study

Exclusion Criteria:

  1. A history of anaphylaxis, serum sickness, meningitis; neuroparalytic events such as encephalitis, transient paralysis; Guillain-Barré Syndrome; myelitis; retrobulbar neuritis; history of prior or current hearing loss as assessed by quantitative audiometry; or multiple sclerosis
  2. Current use of any medications that may be associated with impaired immune responsiveness
  3. Allergy treatment with antigen injections within 60 days before first vaccination or that are planned through the end of the study.
  4. Receipt of immunoglobulins and/or any blood products within the 60 days before first vaccination or that are planned through the end of the study.
  5. Current pregnancy or lactation
  6. Known allergic reactions to 1) any rabies vaccine; 2) any components of HDCV (human albumin, neomycin sulfate, phenol red, beta-propiolactone); 3) any components of LASSARAB +aPHAD-SE (LASSARAB, Tris-HCI, L-Arginine, (3D -(6-Acyl) PHAD, Squalene Redistilled, DMPC, Vitamin E Dry Powder).
  7. History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions to drug or vaccine products.
  8. Has a significant acute illness (with or without fever), as determined by the site PI or appropriate sub-investigator, within 72 hours prior to enrollment
  9. Receipt of a rabies vaccine or an antibody therapeutic product for treating rabies or a Lassa fever vaccine any time before the first planned study vaccination.
  10. Receipt of another experimental agent or intervention within 60 days before first vaccination or plans to do so before the end of the study.
  11. Received or plans to receive any other vaccine in the 2 weeks prior to the first vaccination through Day 61 (32 days after the last study treatment).
  12. Received or plans to receive any live vaccine in the 4 weeks prior to first vaccination through Day 61 (32 days after the last study treatment).
  13. Self-reported or known history of alcoholism within the last 2 years.
  14. Any condition that, in the judgment of the investigator, precludes participation because it could affect participant safety or endpoint assessment.
  15. Has tattoos, scars, or other marks which would, in the opinion of the investigator, interfere with assessment of the vaccination site.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Cohort 1 - LASSARAB+ aPHAD-SE Vaccine at 700rU or Active Comparator (AC)

4:1 randomization to investigational vaccine or active comparator (n=5)

Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection

Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M

Autres noms:
  • Imovax
Expérimental: Cohort 2 - LASSARAB+ aPHAD-SE Vaccine at 700rU or 1400rU or AC

11:4:3 randomization to investigational vaccine dose 700rU or 1400rU or active comparator (n=18)

Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection

Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M

Autres noms:
  • Imovax

Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection

Expérimental: Cohort 3 - LASSARAB+ aPHAD-SE Vaccine at 1400rU Single or Double or AC or AC/Placebo

11:2:4:1 randomization to investigational vaccine single dose at 1400rU or investigational vaccine (2 doses) at 14rU or active comparator or active comparator and normal saline placebo

Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M

Autres noms:
  • Imovax

Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection

Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg

Expérimental: Cohort 4 - LASSARAB+ aPHAD-SE Vaccine at 1400rU (single) or AC/Placebo

11:3 randomization to investigational vaccine (2 doses) at 14rU or active comparator and normal saline placebo

Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M

Autres noms:
  • Imovax

Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection

Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of participants experiencing solicited local and systemic events
Délai: From Day 1 through Day 8 for the first vaccination and from Day 29 through Day 36 for the second vaccination, as applicable

Number of participants experiencing solicited local and systemic reactogenicity Adverse Events (AEs)

From Day 1 through Day 8 for the first vaccination and from Day 29 through Day 36 for the second vaccination, as applicable
Percentage of participants experiencing solicited local and systemic events
Délai: From Day 1 through Day 8 for the first vaccination and from Day 29 through Day 36 for the second vaccination, as applicable

Percentage of participants experiencing solicited local and systemic reactogenicity Adverse Events (AEs)

From Day 1 through Day 8 for the first vaccination and from Day 29 through Day 36 for the second vaccination, as applicable
Number of participants experiencing unsolicited events
Délai: Day 1 through Day 61

Number of participants experiencing any unsolicited AEs

Day 1 through Day 61
Percentage of participants experiencing unsolicited events
Délai: Day 1 through Day 61

Percentage of participants experiencing any unsolicited AEs

Day 1 through Day 61
Number of participants experiencing Serious Adverse Events (SAEs)
Délai: Day 1 through Day 394

Number of participants experiencing SAEs

Day 1 through Day 394
Percentage of participants experiencing Serious Adverse Events (SAEs)
Délai: Day 1 through Day 394

Percentage of participants experiencing SAEs

Day 1 through Day 394
Number of participants experiencing Medically-Attended Adverse Events (MAAEs)
Délai: Day 1 through Day 394

Number of participants experiencing MAAEs

Day 1 through Day 394
Percentage of participants experiencing Medically-Attended Adverse Events (MAAEs)
Délai: Day 1 through Day 394

Percentage of participants experiencing MAAEs

Day 1 through Day 394
Number of participants experiencing New-Onset Chronic Medical Conditions (NOCMCs)
Délai: Day 1 through Day 394

Number of participants experiencing NOCMCs

Day 1 through Day 394
Percentage of participants experiencing New-Onset Chronic Medical Conditions (NOCMCs)
Délai: Day 1 through Day 394

Percentage of participants experiencing NOCMCs

Day 1 through Day 394
Number of participants experiencing Potential Immune-Mediated Medical Conditions (PIMMCs)
Délai: Day 1 through Day 394

Number of participants experiencing PIMMCs

Day 1 through Day 394
Percentage of participants experiencing Potential Immune-Mediated Medical Conditions (PIMMCs)
Délai: Day 1 through Day 394

Percentage of participants experiencing PIMMCs

Day 1 through Day 394
Number of participants experiencing Adverse Event of Special Interest (AESI)
Délai: Day 1 through Day 394

Number of participants experiencing Adverse Event of Special Interest (AESI) - new onset sensorineural hearing loss (SNHL)

Day 1 through Day 394
Percentage of participants experiencing Adverse Event of Special Interest (AESI)
Délai: Day 1 through Day 394

Percentage of participants experiencing Adverse Event of Special Interest (AESI) - new onset sensorineural hearing loss (SNHL)

Day 1 through Day 394
Number of participants experiencing clinical laboratory AEs
Délai: Day 1 through Day 61

Number of participants experiencing clinical laboratory AEs

Day 1 through Day 61
Percentage of participants experiencing clinical laboratory AEs
Délai: Day 1 through Day 61

Percentage of participants experiencing clinical laboratory AEs

Day 1 through Day 61

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

13 janvier 2025

Achèvement primaire (Réel)

11 mai 2026

Achèvement de l'étude (Réel)

11 mai 2026

Dates d'inscription aux études

Première soumission

30 juillet 2024

Première soumission répondant aux critères de contrôle qualité

7 août 2024

Première publication (Réel)

9 août 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

21 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner